Europe
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
AstraZeneca signed a deal with Beijing-based Shenzhen Kangtai Biological Products to manufacture AstraZeneca and the University of Oxford’s COVID-19 vaccine in mainland China.
Eliquis generic was approved by FDA to prevent strokes, blood clots etc. But there were some legal issues which recently got stave off. Know more about it here.
PRESS RELEASES